ARTY Trademark

Trademark Overview


On Wednesday, March 10, 2021, a trademark application was filed for ARTY with the United States Patent and Trademark Office. The USPTO has given the ARTY trademark a serial number of 90572029. The federal status of this trademark filing is REGISTERED as of Tuesday, September 19, 2023. This trademark is owned by Immunocore Limited. The ARTY trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for the treatment of cancer, viral infections, and tumorous diseases; biological preparations for the treatment of viral infections; biological preparations for medical use for the treatment of tumorous diseases; immunotherapeutic drugs, namely, pharmaceutical preparations for the treatment of cancer, viral infections, tumorous diseases; reagents for medical use; diagnostic preparations for medical purposes; diagnostic reagents for medical use; medical diagnostic reagents used in connection with drug discovery, namely, the identification of pharmaceutical targets and the development of molecules to be used for medicinal or therapeutic purposes; medical diagnostic reagents used in connection with protein engineering and biological drug development; all of the foregoing excluding treatment of osteoarticular disorders, of bone and joint pathologies, of musculoskeletal pathologies and of degenerative and chronic inflammatory pathologies, vertebral-spinal patholo...

Scientific and technological services, namely, pharmaceutical research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; research and development in the biotechnology field; drug discovery, namely, the identification of pharmaceutical targets and the development of molecules to be used for medicinal or therapeutic purposes; protein engineering and biological drug development; provision of information and consultancy in relation to the aforesaid services; all of the foregoing excluding treatment of osteoarticular disorders, of bone and joint pathologies, of musculoskeletal pathologies and of degenerative and chronic inflammatory pathologies, vertebral-spinal pathologies and disorders, degenerative and chronic inflammatory pathologies, inflammatory pathologies due to rheumatic disorders, or trauma or auto-immune conditions
arty

General Information


Serial Number90572029
Word MarkARTY
Filing DateWednesday, March 10, 2021
Status700 - REGISTERED
Status DateTuesday, September 19, 2023
Registration Number7166648
Registration DateTuesday, September 19, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 25, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of cancer, viral infections, and tumorous diseases; biological preparations for the treatment of viral infections; biological preparations for medical use for the treatment of tumorous diseases; immunotherapeutic drugs, namely, pharmaceutical preparations for the treatment of cancer, viral infections, tumorous diseases; reagents for medical use; diagnostic preparations for medical purposes; diagnostic reagents for medical use; medical diagnostic reagents used in connection with drug discovery, namely, the identification of pharmaceutical targets and the development of molecules to be used for medicinal or therapeutic purposes; medical diagnostic reagents used in connection with protein engineering and biological drug development; all of the foregoing excluding treatment of osteoarticular disorders, of bone and joint pathologies, of musculoskeletal pathologies and of degenerative and chronic inflammatory pathologies, vertebral-spinal pathologies and disorders, degenerative and chronic inflammatory pathologies, inflammatory pathologies due to rheumatic disorders, or trauma or auto-immune conditions
Goods and ServicesScientific and technological services, namely, pharmaceutical research and design relating thereto; pharmaceutical research and development services; pharmaceutical testing and clinical trials; research and development in the biotechnology field; drug discovery, namely, the identification of pharmaceutical targets and the development of molecules to be used for medicinal or therapeutic purposes; protein engineering and biological drug development; provision of information and consultancy in relation to the aforesaid services; all of the foregoing excluding treatment of osteoarticular disorders, of bone and joint pathologies, of musculoskeletal pathologies and of degenerative and chronic inflammatory pathologies, vertebral-spinal pathologies and disorders, degenerative and chronic inflammatory pathologies, inflammatory pathologies due to rheumatic disorders, or trauma or auto-immune conditions

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 10, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, June 10, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameImmunocore Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressAbingdon, Oxfordshire OX144RY
GB

Party NameImmunocore Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressAbingdon, Oxfordshire OX144RY
GB

Party NameImmunocore Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressAbingdon, Oxfordshire OX144RY
GB

Trademark Events


Event DateEvent Description
Tuesday, September 19, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, September 19, 2023REGISTERED-PRINCIPAL REGISTER
Thursday, August 10, 20231(B) BASIS DELETED; PROCEED TO REGISTRATION
Tuesday, June 20, 2023NOTICE OF ALLOWANCE CANCELLED
Thursday, August 10, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, June 20, 2023TEAS DELETE 1(B) BASIS RECEIVED
Tuesday, June 20, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 25, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 25, 2023PUBLISHED FOR OPPOSITION
Wednesday, April 5, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 22, 2023ELECTRONIC RECORD REVIEW COMPLETE
Monday, March 20, 2023EXPARTE APPEAL TERMINATED
Friday, March 17, 2023ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Thursday, March 16, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 28, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Friday, September 16, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, September 16, 2022LETTER OF SUSPENSION E-MAILED
Friday, September 16, 2022SUSPENSION LETTER WRITTEN
Thursday, September 8, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, September 8, 2022EX PARTE APPEAL-INSTITUTED
Thursday, September 8, 2022JURISDICTION RESTORED TO EXAMINING ATTORNEY
Thursday, September 8, 2022EXPARTE APPEAL RECEIVED AT TTAB
Tuesday, March 8, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, March 8, 2022FINAL REFUSAL E-MAILED
Tuesday, March 8, 2022FINAL REFUSAL WRITTEN
Monday, March 7, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 7, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 7, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 6, 2021NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Wednesday, October 6, 2021EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Wednesday, October 6, 2021COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Wednesday, October 6, 2021EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Monday, October 4, 2021ASSIGNED TO EXAMINER
Thursday, June 24, 2021PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Thursday, June 17, 2021ASSIGNED TO LIE
Thursday, June 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 29, 2021TEAS VOLUNTARY AMENDMENT RECEIVED
Saturday, March 13, 2021NEW APPLICATION ENTERED